Medicine

Molecular profiling of BRAF-V600E-mutant metastatic colon cancer in the phase\u00e2 $ 3 SIGN CRC trial

.Competing interests.S.K.: Supply as well as Other Possession Interests: Iylon, Lutris, MolecularMatch, Navire. Consulting or Advisory Part: AbbVie, Amal Therapies, AstraZeneca/MedImmune, Bayer Health And Wellness, Bicara Rehabs, Boehringer Ingelheim, Boston Biomedical, Carina Biotech, Daiichi Sankyo, EMD Serono, Endeavor BioMedicines, Blaze Biosciences, Genentech, Gilead Sciences, GSK, HalioDx, Holy Stone Health Care, Inivata, Ipsen, Iylon, Jacobio, Jazz Music Drugs, Lilly, Lutris, Merck, Mirati Therapies, Natera, Novartis, Numab, Pfizer, Pierre Fabre, Redx Pharma, Repare Rehab, Servier, Xilis. Study Funding: Amgen (Inst), Collection BioPharma (Inst), Biocartis (Inst), Daiichi Sankyo (Inst), EMD Serono (Inst), Genentech/Roche (Inst), Guardant Health And Wellness (Inst), Lilly (Inst), MedImmune (Inst), Novartis (Inst), Sanofi (Inst). D.A.M.: Work: Previously Pfizer. Sell and Various Other Possession Interests: Pfizer. J.P.: Job: In The Past Pfizer. Sell and Other Ownership Interests: Pfizer. F.C.: Consulting or even Advisory Duty: Amgen, Bayer, Merck KGaA, Pfizer, Roche/Genentech. Analysis Backing: Amgen (Inst), Bayer (Inst), Bristol Myers Squibb (Inst), Ipsen (Inst), Merck KGaA (Inst), MSD (Inst), Roche/Genentech (Inst), Servier (Inst), Symphogen (Inst). J.D.: Consulting or Advisory Function: Amgen (Inst), Bayer, BeiGene, Daiichi Sankyo, Eisai, GSK, Merck KGaA, Pierre Fabre. Study Financing: AstraZeneca/MedImmune (Inst), BeiGene (Inst), Bionomics (Inst), Bristol Myers Squibb (Inst), GSK (Inst), Lilly (Inst), Novartis (Inst), Roche (Inst). E.V.C.: Consulting or even Advisory Duty: AbbVie, Agenus, ALX, Amgen, Arcus Biosciences, Astellas Pharma, AstraZeneca, Bayer, BeiGene, BioNTech, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Debiopharm, ElmediX, Eisai, GSK, Hookipa Biotech, Incyte, Ipsen, Lilly, Merck Sharp &amp Dohme, Merck KGaA, Mirati, Novartis, Nordic, Pierre Fabre, Pfizer, Roche, Seagen, Servier, Simcere, Takeda, Taiho Drug, Terumo. H.S.W.: Consulting or Advisory Part: Amgen, Bayer, Bristol Myers Squibb (Celgene), Boehringer Ingelheim (DMC), BTG, EXACT Therapies, Erytech Pharma, Incyte, Merck KGaA, Oaktree Life Sciences, OncoSil, Pfizer, Pierre Fabre, Roche/Genentech, Seagen, Servier, County, Sirtex Medical, Takeda (Hutchinson Medication), Zymeworks. Analysis Funding: Merck KGaA (Inst), MSD (Inst), Pfizer (Inst), Sirtex Medical (Inst). T.Y.: Honoraria: Bayer Yakuhin, Chugai Pharma, Merck KGaA, MSD, Ono Drug, Sumitomo Corp., Takeda. Study Backing: Amgen (Inst), Boehringer Ingelheim (Inst), Chugai Pharma (Inst), Daiichi Sankyo Co., Ltd. (Inst), Eisai, FALCO Biosystems, Genomedia (Inst), Molecular Wellness, MSD (Inst), Nippon Boehringer Ingelheim, Ono Drug (Inst), Pfizer (Inst), Roche Diagnostics, Sanofi (Inst), Sumitomo Dainippon (Inst), Sysmex (Inst), Taiho Drug (Inst). H.S.: Job: Pfizer. Stock as well as Various Other Ownership Interests: Pfizer. X.Z.: Work: Pfizer. Stock as well as Other Ownership Stakes: Pfizer. Patents, Nobilities, Various Other Trademark: Johns Hopkins Educational Institution. P.H.: Work: Pfizer. Inventory and Other Possession Claims: Pfizer. T.X.: Employment: Pfizer. Supply and Other Ownership Claims: Pfizer. R.Y.: Consulting or Advisory Function: Variety BioPharma/Pfizer, Mirati Therapeutics, Zai Laboratory, Amgen. Investigation Backing: Assortment BioPharma (Inst), Boehringer Ingelheim (Inst), Mirati Therapy (Inst), Pfizer (Inst), Daiichi Sankyo (Inst). J.T.: Consulting or Advisory Function: Collection BioPharma, AstraZeneca, Bayer, Boehringer Ingelheim, Chugai Pharma, Daiichi Sankyo, F. Hoffmann-La Roche, Genentech, HalioDx, Hutchison MediPharma, Ikena Oncology, Inspirna Inc., IQVIA, Lilly, Menarini, Merck Serono, Merus, Mirati Therapies, MSD, NeoPhore, Novartis, Ona Rehabs, Orion Medical, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Scandion Oncology, Scorpion Rehab, Seagen Inc., Servier, Taiho Drug, Tessa Therapy, TheraMyc. Various Other Connection: Amgen, Variety Biopharma, BeiGene, Boehringer Ingelheim, BMS, Cancer Analysis UK, Celgene, Debiopharm, F. Hoffman-La Roche, Fundaciu00c3 u00b3 n Cientu00c3fica de Los Angeles Asociaciu00c3 u00b3 n Espau00c3 u00b1 ola Converse el Cu00c3 u00a1 ncer, Genentech, HalioDX, Hutchinson Medipharma, Imedex, Janssen-Cilag, MedImmune, Medscape, Menarini, Merck Wellness KGaA, MJH Lifestyle Sciences, MSD, Merus, Mirati, Novartis, Oniria Therapies, PeerView Principle for Medical Learning, Pfizer, PharmaMar, Physicansu00e2 $ Education And Learning Information, Sanofi-Aventis, Servier, Taiho Drug.